Trial Profile
Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IM19 chimeric antigen receptor T cell therapy Beijing Immunochina Medical Science and Technology (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 28 Apr 2018 Planned number of patients changed from 20 to 60.
- 11 May 2017 New trial record